Introduction
The Material Adverse Effect clause is the buyer's primary contractual protection against significant deterioration in the target's business between signing and closing. In healthcare, the MAE clause requires healthcare-specific carveouts because the sector is subject to risks (reimbursement changes, regulatory actions, clinical failures, pandemic disruptions) that could constitute material adverse effects but are considered inherent industry risks that the buyer should price into the deal, not use as an exit right.
How Healthcare MAE Clauses Differ
A standard MAE clause in a non-healthcare deal allows the buyer to terminate if events cause a material adverse effect on the target's business, financial condition, or results of operations. The clause then carves out broad categories of events that do not constitute an MAE (general economic conditions, industry-wide changes, acts of war). Healthcare deals add sector-specific carveouts that reflect risks unique to the industry.
- MAE Carveout
An exception to the Material Adverse Effect definition that excludes specific types of adverse events from triggering the buyer's right to terminate. If a carveout applies, the adverse event is considered an inherent industry risk that the buyer accepted when it signed the deal, not a basis for walking away. Healthcare-specific carveouts ensure that foreseeable regulatory, reimbursement, and clinical risks do not become pretexts for buyer's remorse during the extended closing period typical of healthcare transactions.
| Healthcare MAE Carveout | What It Covers | Why It Exists |
|---|---|---|
| Reimbursement changes | Medicare/Medicaid rate adjustments, payer contract changes | Reimbursement shifts are foreseeable industry risk |
| FDA regulatory actions | Warning letters, label changes, manufacturing holds | Regulatory risk is inherent in pharma/device |
| Clinical trial results | Negative data readouts, failed endpoints | Clinical risk is priced into biotech valuations |
| Healthcare reform legislation | ACA modifications, IRA implementation, state regulation | Policy changes affect the entire industry |
| Pandemic and public health | Disease outbreaks, public health emergencies | Post-COVID standard inclusion |
The "Durationally Significant" Standard
The legal standard for what constitutes a material adverse effect was clarified in the Delaware Chancery Court's landmark Akorn v. Fresenius decision (2018), which held that an MAE must be "durationally significant," meaning it must substantially affect the company's earning power over a period measured in years, not months or quarters.
This standard is particularly relevant in healthcare because many adverse events (an FDA warning letter, a temporary reimbursement reduction, a clinical trial delay) cause significant short-term disruption but do not necessarily impair long-term earning power. Under the durationally significant standard, a buyer cannot invoke the MAE clause based on a single bad quarter or a temporary regulatory setback.
The next article covers healthcare-specific due diligence, exploring the six critical domains that healthcare transactions must address beyond standard financial and legal diligence.
Free Interview PDF Guide